| | | WHY ARE LIPID FORMULATIONS COMMONLY USED TO ENHANCE BIOAVAILABILITY? | | Enabling formulations becomes more and more necessary to obtain adequate exposure of APIs during (pre)-clinical research. Currently, most registered formulations to improve bioavailability are based on lipidic systems, which make use of intrinsic digestion processes within the GI tract, fa... | | |
| | | DESIGNING AMORPHOUS DISPERSION FORMULATIONS FOR POORLY SOLUBLE DRUGS
| | Many orally administered small molecules have low aqueous solubility, which leads to poor oral absorption. For many of these poorly soluble drugs currently in development, amorphous dispersions are increasingly being used as a formulation approach to improve solubility and oral absorption.... | | |
| |
| | | VIRAL SAFETY BY DESIGN FOR CELL AND GENE THERAPY PRODUCTS | | Together with product efficacy, product safety is an essential characteristic of any medicinal product including cell and gene therapy (C>) biologics. Adventitious agents (viruses, bacteria, mycoplasma, prions, etc) pose a constant risk to these biologics, and, as such, they may impact ... | | |
| | | NEW DRUG PRODUCT DEVELOPMENT USING CONTINUOUS MANUFACTURING | | What is Drug Product Continuous Manufacturing? Is Continuous Manufacturing really worth the effort? "without data, you are just another person with an opinion" What are the challenges implementing CM? Development and tech transfer considerations for CM. Learning Objectives: Demon... | | |
| |